cGVHD Today and Where Axatilimab Fits

Brooke Adams, PharmD, BCOP, describes the clinical reality of third-line cGVHD: patients with relapsed or refractory disease after steroids, calcineurin inhibitors, and at least 1 approved second-line agent. She describes what hitting a ceiling looks like—escalating symptom burden, organ involvement, and functional decline—and positions axatilimab within the unmet need that prompted its development.